A Cost–Consequence Analysis of Preemptive <i>SLCO1B1</i> Testing for Statin Myopathy Risk Compared to Usual Care
There is a well-validated association between <i>SLCO1B1</i> (rs4149056) and statin-associated muscle symptoms (SAMS). Preemptive <i>SLCO1B1</i> pharmacogenetic (PGx) testing may diminish the incidence of SAMS by identifying individuals with increased genetic risk before stat...
Enregistré dans:
| Auteurs principaux: | , , , , , , |
|---|---|
| Format: | article |
| Langue: | EN |
| Publié: |
MDPI AG
2021
|
| Sujets: | |
| Accès en ligne: | https://doaj.org/article/bce280f5a3324b0bba6cd0a0da6a1f6f |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|